Skip to content
Screener

Cytokinetics CYTK Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
-$31.85M-1,091%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-$49.94M-22.4%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
-$34.48M-46.1%
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
$24.72M+37.7%
Medtronic logo
MedtronicMDT
ITG
Integer HoldingsITGR

Other financials

Income statement

See full
Revenue$28.6M-57.1%
Operating income-$179.2M-60.7%
Net income-$198.8M-47.9%
EPS (diluted)-$1.50-33.9%

Balance sheet

See full
Cash & equivalents$255.3M+241%
Total debt$399.0M+31.2%
Total equity-$173.5M+52.9%
Total assets$1.9B+57.0%

Cash flow

See full
Operating cash flow-$159.8M-24.6%
CapEx$4.3M+4.6%
Free cash flow-$164.2M-24.0%

Valuation

See full
Market cap$10.42B+162%
Enterprise value$10.57B+151%
P/S154×+108×

Profitability

See full
Operating margin-1,046.1%+1,858pp
Net margin-1,321.1%+8,702pp
FCF margin-858.2%+1,799pp

Returns & leverage

See full
Return on equity-337.6%
Debt / equity2.2×
Current ratio6.7×-0.1×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338217
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Change in fair value of liabilities related to RPI Transactions2,400(14,600)800(10,700)
Net loss$(198,762)$(134,370)$(404,793)$(295,746)
Net loss per share — basic and diluted$(1.50)$(1.12)$(3.17)$(2.49)
Weighted-average number of shares used in computing net loss per share — basic and diluted132,086119,457127,704118,979
Other comprehensive (loss) gain:
Unrealized loss on available-for-sale securities, net(1,770)(851)(3,608)(1,392)
Foreign currency translation adjustments(444)(852)(848)(1,164)
Comprehensive loss$(200,976)$(136,073)$(409,249)$(298,302)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Cytokinetics's comprehensive income (loss), net of tax, attributable to parent?
Cytokinetics (CYTK) reported comprehensive income (loss), net of tax, attributable to parent of -$200.98M in Q2 2026.
How has Cytokinetics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Cytokinetics's comprehensive income (loss), net of tax, attributable to parent decreased by 47.7% year-over-year, from -$136.07M to -$200.98M.
What is the long-term trend for Cytokinetics's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Cytokinetics's comprehensive income (loss), net of tax, attributable to parent has grown at a 38.1% compound annual growth rate (CAGR), from -$216.33M to -$786.72M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
Comprehensive income is the sum of net income and other comprehensive income items, such as unrealized gains on securities and foreign currency translation adjustments. It provides a broader measure of the change in equity resulting from non-owner sources. It captures the total financial impact of both operational and market-driven events.

Ask your AI about Cytokinetics's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude